Nasdaq GlobeNewswire

Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates


Four late-stage trials underway, targeting schizophrenia, major depressive disorder and insomnia disorder

Planning for commercialization moves forward 

Management to host conference call today at 8:30 a.m. Eastern Time

WALTHAM, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central nervous system (CNS) disorders, today reported key business updates and financial results for the fourth quarter and fiscal year ended December 31, 2017.

"We have initiated four late-stage clinical efficacy trials with two compounds during late 2017, and we are planning to initiate a fifth with a third compound in the near future," said Dr. Remy Luthringer, executive chairman and chief executive officer of Minerva.  "We have also expanded our internal capabilities in the areas of strategic development, market research and commercial expertise as we plan for the transition from late-stage clinical development to the market for our product candidates," said Dr. Luthringer.  "This evolution supports our corporate strategy to develop and commercialize first-in-class products with novel mechanisms of action that address critical needs in targeted CNS areas, led by roluperidone (MIN-101) for negative symptoms in patients with schizophrenia." 

Roluperidone (MIN-101):

  • In December 2017, the first patient was screened in the pivotal Phase 3 clinical trial of roluperidone as monotherapy for negative symptoms in patients diagnosed with schizophrenia.  This multicenter, randomized, double-blind, parallel-group, placebo-controlled, 12-week trial will evaluate the efficacy and safety of 32 milligrams (mg) and 64 mg of roluperidone in adult patients with negative symptoms of schizophrenia.  The 12-week study will be followed by a 40-week, open-label extension period during which patients on drug will continue receiving their original dose and patients on placebo will receive either 32 mg or 64 mg of roluperidone.
  • The effect of roluperidone as compared to placebo will be determined with respect to the primary endpoint, the change from baseline in negative symptoms using the Positive and Negative Syndrome Scale (PANSS) Marder's negative symptoms factor score (NSFS) over the 12-week double-blind treatment period.  The key secondary endpoint is the effect of roluperidone compared to placebo as measured by the change from baseline in the Personal and Social Performance (PSP) total score over the same period.  Additional secondary endpoints will be the Clinical Global Impression of Severity (CGI-S) score and safety and tolerability.
  • Approximately 500 patients are expected to be enrolled at approximately 60 clinical sites in the U.S. and Europe, with about 30 percent of patients coming from the U.S.  Top-line results from the 12-week double blind phase of this trial are expected in the first half of 2019.

Seltorexant (MIN-202 or JNJ-42847922), under joint development with Janssen Pharmaceutica NV (Janssen):

  • In September 2017, the first patient was enrolled in a Phase 2b multi-center, double-blind, randomized, parallel-group, placebo-controlled, adaptive-dose finding clinical trial of seltorexant as adjunctive therapy to antidepressants in adult patients with major depressive disorder (MDD) who have responded inadequately to antidepressant therapy.  The primary objectives of this study are: (1) to assess the dose-response relationship and augmentation of antidepressant effect of up to three doses of seltorexant (10 mg, 20 mg, and 40 mg), and (2) to assess the safety and tolerability of seltorexant compared to placebo.  Approximately 280 patients are planned to be enrolled at more than 85 clinical sites in the U.S., Europe, Russia and Japan.
  • In December 2017, the first patient was enrolled in a Phase 2b multi-center, double-blind, randomized, parallel-group, active- and placebo-controlled dose finding clinical trial of seltorexant in patients with insomnia disorder.  The primary objective is to assess the dose-response of three doses of seltorexant (5, 10 and 20 milligrams daily) compared to placebo on sleep onset as measured by the latency to persistent sleep using polysomnography (PSG).  The key secondary objective is to assess the dose-response of these three doses compared to placebo on wake after sleep onset over the first six hours using PSG.  In addition, the effects of seltorexant on sleep and cognition will be compared to those effects of zolpidem to determine potential differences between the compounds.  Approximately 360 patients are planned to be randomized at clinical sites in the U.S., European Union and Japan.  
  • In December 2017, the first patient was enrolled in a Phase 2b multi-center, double-blind, randomized, flexible-dose, parallel-group study to assess the efficacy of flexibly dosed seltorexant compared to flexibly dosed quetiapine as adjunctive therapy to a baseline antidepressant drug in delaying time to all-cause discontinuation of study drug over a 6-month treatment period.  Approximately 100 patients are planned to be randomized at approximately 34 sites in the U.S. to receive either flexibly dosed seltorexant, 20 mg or 40 mg, or flexibly dosed quetiapine XR, 150 mg or 300 mg.
  • Under the amended agreement with Janssen that became effective in August, 2017, Janssen has waived its right to royalties on seltorexant insomnia sales in the Minerva territory (the European Union, Switzerland, Liechtenstein, Iceland and Norway).  Minerva retains all of its rights to seltorexant, including commercialization for the treatment of insomnia and as an adjunctive therapy for MDD, which includes an exclusive license in the Minerva Territory.  Minerva has also assumed strategic control for the clinical development of seltorexant in insomnia but has no further financial obligations until the Phase 2b development milestone is complete, which is expected to occur in the second half of 2019.  


  • Building upon the results of an earlier Phase 2a trial with MIN-117 in Europe, the Company is planning to initiate a Phase 2b trial in MDD in the U.S. and Europe in early 2018.  The Company expects to enroll patients with MDD who also have symptoms of anxiety.  In preparation for this trial, a food effect study was recently completed, and no food effect was observed on the PK exposure parameters, therefore allowing dosing with or without food.


  • The Company is continuing the pre-clinical development of MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, for the treatment of Parkinson's disease and potentially for other neurodegenerative disorders. The next planned steps in this program include the completion of the pre-clinical package to enable the filing of an Investigational New Drug application (IND) in the U.S. and/or an Investigational Medicinal Product Dossier in Europe, and pending acceptance by regulatory authorities, the initiation of Phase 1 clinical testing thereafter.

Fourth Quarter and Year Ended 2017 Financial Results

  • Net Income (Loss):  Net income was $0.2 million for the fourth quarter of 2017, or income per share of $0.00 (basic and diluted), compared to a net loss of $9.4 million for the fourth quarter of 2016, or a loss per share of $0.27 (basic and diluted).  Net loss was $31.5 million for the year ended December 31, 2017, or a loss per share of $0.83 (basic and diluted), compared to a net loss of $31.0 million, or a loss per share of $0.99 (basic and diluted), for the year ended December 31, 2016.
  • R&D Expenses: Research and development (R&D) expenses were $6.5 million in the fourth quarter of 2017 and 2016.  R&D expenses were $30.3 million for the year ended December 31, 2017, compared to $20.4 million for the year ended December 31, 2016.  This increase in R&D expenses primarily reflects higher development expenses under the seltorexant program, increased expenses for the MIN-101 program, an increase in personnel costs and an increase in non-cash stock-based compensation expenses. These amounts were partially offset by lower costs due to the completion of the Phase 2a clinical trial of MIN-117.
  • G&A Expenses: General and administrative (G&A) expenses were $3.0 million in the fourth quarter of 2017, compared to $2.7 million in the fourth quarter of 2016.  G&A expenses were $10.9 million for the year ended December 31, 2017, compared to $9.8 million for the year ended December 31, 2016.  The increase in general and administrative expenses was primarily due to an increase in professional fees and an increase in non-cash stock-based compensation expenses.
  • Benefit for income taxes: Benefit for income taxes was $9.4 million in the fourth quarter of 2017, compared to zero in the fourth quarter of 2016. Benefit for income taxes was $9.4 million for the year ended December 31, 2017, compared to zero for the year ended December 31, 2016. On December 22, 2017, the United States enacted tax reform legislation commonly known as the Tax Cuts and Jobs Act (the "Act"), resulting in significant modifications to existing law. In the year ended December 31, 2017, these tax reforms resulted in a benefit of $9.4 million related to future implications of indefinite lived deferred tax positions.  
  • Cash Position: Cash, cash equivalents and marketable securities as of December 31, 2017 were approximately $133.2 million, compared to $83.0 million as of December 31, 2016.  During 2017, the Company received approximately $41.6 million in net proceeds from a July 2017 public offering of common stock, proceeds from the exercise of common stock warrants of $9.4 million, proceeds from the exercise of common stock options of $1.1 million, and $30 million in an upfront payment in connection with the amendment to the Company's Co-Development and License Agreement with Janssen for seltorexant. Minerva presently expects that its existing cash and cash equivalents will be sufficient to meet its anticipated capital requirements for at least the next 12 months from today.  The assumptions upon which this estimate is based are routinely evaluated and may be subject to change. 

Conference Call Information:

Minerva Neurosciences will host a conference call and live audio webcast today at 8:30 a.m. Eastern Time to discuss the quarter and recent business activities.  To participate, please dial (877) 312-5845 (domestic) or (765) 507-2618 (international) and refer to conference ID 1581007.

The live webcast can be accessed under "Events and Presentations" in the Investors and Media section of Minerva's website at  The archived webcast will be available on the website beginning approximately two hours after the event for 90 days.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases.  Minerva's proprietary compounds include: roluperidone (MIN-101), in Phase 3 clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922) in Phase 2b clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease.  Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV."  For more information, please visit

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties.  Forward-looking statements include statements herein with respect to the timing and scope of future clinical trials and results of clinical trials with roluperidone, seltorexant, MIN-117 and MIN-301; the timing and scope of future clinical trials and results of clinical trials with these compounds; the clinical and therapeutic potential of these compounds; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management's ability to successfully achieve its goals.  These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone, seltorexant, MIN-117 and MIN-301 will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic products will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions.  These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on March 12, 2017.  Copies of reports filed with the SEC are posted on our website at The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.   

  December 31, December 31,  
  2017     2016    
  (in thousands)  
Current Assets:      
Cash and cash equivalents $   26,052   $   82,981    
Marketable securities     102,109       -     
Restricted cash     80       80    
Prepaid expenses and other current assets     1,299       803    
Total current assets     129,540       83,864    
Marketable securities - noncurrent     5,023       -     
Equipment, net     51       10    
Other non-current assets     15       -     
In-process research and development     34,200       34,200    
Goodwill     14,869       14,869    
Total Assets $   183,698   $   132,943    
Current Liabilities:      
Notes payable - current portion $   3,962   $   4,854    
Accounts payable     1,436       1,467    
Accrued expenses and other current liabilities     1,439       816    
Accrued collaborative expenses     -        2,548    
Total current liabilities     6,837       9,685    
Long-Term Liabilities:      
Notes payable - noncurrent     -        3,841    
Deferred taxes     4,057       13,434    
Deferred revenue     41,176       -     
Other non-current liabilities     30       -     
Total liabilities     52,100       26,960    
Stockholders' Equity:      
Common stock     4       4    
Additional paid-in capital     295,975       238,837    
Accumulated deficit     (164,381 )     (132,858 )  
Total stockholders' equity     131,598       105,983    
Total Liabilities and Stockholders' Equity $   183,698   $   132,943    


    Three Months Ended December 31,   Twelve Months Ended December 31,
    (in thousands, except per share amounts)   (in thousands, except per share amounts)
      2017     2016       2017     2016  
Revenues   $   -    $   -      $   -    $   -   
Operating expenses:            
Research and development       6,541       6,499         30,256       20,440  
General and administrative       2,991       2,739         10,914       9,751  
Total operating expenses       9,532       9,238         41,170       30,191  
Foreign exchange losses       (11 )     4         (57 )     (23 )
Investment income       434       61         942       198  
Interest expense       (105 )     (232 )       (614 )     (1,030 )
Loss before income taxes       (9,214 )     (9,405 )       (40,899 )     (31,046 )
Benefit for income taxes       (9,376 )     -          (9,376 )     -   
Net income (loss)   $   162   $   (9,405 )   $   (31,523 ) $   (31,046 )
Loss per share:            
Basic and diluted   $   0.00   $   (0.27 )   $   (0.83 ) $   (0.99 )
Weighted average shares:            
Basic and diluted       38,710       34,852         37,937       31,514  

Contact :

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Barings Alternative Investments Expands Aviation Investment Platform Through Partnership with Genesis Aircraft Services23.3.2018 15:00Pressemelding

CHARLOTTE, N.C., March 23, 2018 (GLOBE NEWSWIRE) -- Barings Alternative Investments, part of Barings LLC, one of the world's leading financial services firms, announced today the expansion of its aircraft leasing platform on behalf of the firm's institutional fund clients through Genesis Aircraft Services Limited. To facilitate new aircraft acquisitions on behalf of Barings' clients, Genesis will increase existing capabilities to now include all commercial, technical, portfolio and legal management functions required of a full-service premier owner and lessor of commercial aircraft. As part of its increased capabilities, Karl Griffin will join Genesis as Chief Commercial & Investment Officer and will also be appointed to the Genesis Board of Directors effective May 2018; Anna Reimers will join Genesis as Chief Legal Officer; and John McMahon will be appointed to Genesis' Board as an independent director. Griffin is currently the Chief Operating Officer at DAE Capital, an aircraft leasi

Agrisolutions Acquires Trinity23.3.2018 12:00Pressemelding

HAMILTON, Ontario, March 23, 2018 (GLOBE NEWSWIRE) -- Venanpri Group's Agrisolutions division, which services the global agricultural marketplace with its Ingersoll and Bellota brands, announced today the acquisition of Trinity Logistics Corporation ("Trinity"). Based in the U.S., Trinity provides supply-chain solutions relating to fasteners and other components to leading global OEMs that produce mission critical machinery for the agricultural and construction end markets. The terms of the transaction were not disclosed. Headquartered in Davenport, Iowa, Trinity has established ten strategically located service facilities throughout the United States. Trinity specializes in the supply of standard and custom components through vendor managed inventory programs and other arrangements tailored to customer needs. Trinity utilizes its industry leading technology to improve the flow of products, services and information across the supply chain resulting in excellence in the operations of it

Comodo CA Sees 35 Percent Year-Over-Year Increase in EV Certificates22.3.2018 15:47Pressemelding

EV SSL will be a topic of discussion at the Comodo CA booth during RSA 2018 CLIFTON, N.J., March 22, 2018 (GLOBE NEWSWIRE) -- Comodo CA, a worldwide leader in digital identity solutions, will address evolving cyberthreats and the increasing importance Extended Validation (EV) TLS/SSL certificates play in securing websites and inspiring consumer trust at the RSA Conference 2018, San Francisco, April 16 - 20. According to the Feb 2018 Netcraft report, Comodo CA has seen a 35 percent year-over-year increase of EV certificate units* making it one of the fastest growing providers of high assurance certificates. The volume of EV certificates globally also saw a record year in 2017 as more and more businesses adopt EV as standard practice for their websites. The demand for stronger, more secure EV certificates comes in the wake of increased phishing websites using Domain Validated (DV) certificates. Phishing websites imitate legitimate websites to steal customers' funds and identities. Phishi

CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody22.3.2018 14:43Pressemelding

SAN DIEGO, March 22, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced today a strategic licensing agreement with CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies. The agreement gives CBT exclusive world-wide development and commercialization rights to a novel, recombinant, human monoclonal antibody which targets a differentiated epitope on the cytotoxic T-lymphocyte antigen-4 (CTLA-4) molecule. Binding of this antibody to CTLA-4 blocks the interaction of CTLA-4 with its ligands CD80/CD86 thus allowing the cytotoxic T cells to function actively. Under the terms of this global licensing agreement, CBT gain

Cloudflare Announces Mobile SDK to Monitor Network Performance for Applications22.3.2018 14:00Pressemelding

New free solution delivers network analytics to any mobile app developer SAN FRANCISCO, March 22, 2018 (GLOBE NEWSWIRE) -- Cloudflare, the leading Internet performance and security company, today announced the Cloudflare Mobile SDK, a free solution that enables any mobile app developer to understand network performance and metrics. Consumers are frustrated by mobile apps that are slow, crash, or deliver errors that degrade the user experience. For mobile app developers, a bad user experience means poor reviews, lower engagement, and reduced conversion on business metrics. Delivering consistent app performance requires focusing on every link in the chain: app code, network calls between the app and edge networks, and server infrastructure. There are a number of solutions that give developers analytics on their applications, but there has never been a way for app developers to understand how often their apps fail due to network errors. App developers easily integrate the Cloudflare Mobil

Compuware: Survey Shows Critical Mainframe Workloads Increasing While Mainframe Staff Losses Remain Unfilled22.3.2018 13:00Pressemelding

Many Organizations Not Measuring, Prioritizing Vital Key Performance Indicators 57 percent of enterprises with a mainframe currently run more than half of their business-critical applications on the platform-with that number expected to increase to 64 percent by next year. 72 percent of customer-facing applications are completely or very dependent on mainframe processing. Enterprises have only replaced 37 percent of the mainframe workforce lost over the past five years. Many organizations surveyed are not currently measuring velocity or efficiency key performance indicators, putting them at a disadvantage in the digital age. DETROIT, March 22, 2018 (GLOBE NEWSWIRE) -- The mainframe is becoming more important to large enterprises, with the percentage of organizations running at least half their business-critical applications on that platform expected to increase next year. However, the loss of skilled mainframe staff, and the failure to subsequently fill these positions, pose significan

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom